Institute for Pharmacy and Food Chemistry, University of Wurzburg, Am Hubland, DE-97074 Wurzburg, Germany.
J Control Release. 2012 Jul 20;161(2):198-213. doi: 10.1016/j.jconrel.2011.10.001. Epub 2011 Oct 8.
Osteoporosis represents a major public health burden especially considering the aging populations worldwide. Drug targeting will be important to better meet these challenges and direct the full therapeutic potential of therapeutics to their intended site of action. This review has been organized in modules, such that scientists working in the field can easily gain specific insight in the field of bone targeting for the drug class they are interested in. We review currently approved and emerging treatment options for osteoporosis and discuss these in light of the benefit these would gain from advanced targeting. In addition, established targeting strategies are reviewed and novel opportunities as well as promising areas are presented along with pharmaceutical strategies how to render novel composites consisting of a drug and a targeting moiety responsive to bone-specific or disease-specific environmental stimuli. Successful implementation of these principles into drug development programs for osteoporosis will substantially contribute to the clinical success of anti-catabolic and anabolic drugs of the future.
骨质疏松症是一个主要的公共卫生负担,特别是考虑到全球人口老龄化。药物靶向将是应对这些挑战的重要手段,以便将治疗药物的全部治疗潜力引导到其预期的作用部位。本综述以模块的形式组织,以便从事该领域工作的科学家可以轻松地获得他们感兴趣的药物类别在骨靶向领域的具体见解。我们回顾了目前批准和新兴的骨质疏松症治疗选择,并根据这些治疗方法从先进的靶向治疗中获得的益处进行了讨论。此外,我们还回顾了已建立的靶向策略,并提出了新的机会和有前途的领域,以及如何使由药物和靶向部分组成的新型复合材料对骨骼特异性或疾病特异性环境刺激物产生反应的药物策略。将这些原则成功地应用于骨质疏松症的药物开发计划中,将为未来抗分解代谢和合成代谢药物的临床成功做出重大贡献。